ImmunisBio's Technology Export to Malaysia Progresses Smoothly

[Asia Economy Reporter Hyungsoo Park] Immunis Bio announced on the 28th that the NK immune cell therapy (MYJ1633), which is being licensed to Malaysia, is gaining attention for its high efficacy.

Immunis Bio signed a technology export contract for MYJ1633 with Malaysia's NK Biosell in March 2020. MYJ1633 is being used to treat cancer patients and patients with autoimmune diseases.

In a stage 4 malignant melanoma patient, the tumor size decreased after 4 administrations of MYJ1633. A patient with persistent recurrent Graves' disease (a type of thyroid autoimmune disease), whose hormone levels were not controlled despite medication, also showed partial recovery of hormone levels to normal after 2 administrations of MYJ1633.

NK Biosell achieved about 100 cultures of the MYJ1633 therapeutic agent in the first half of this year alone. In June, they signed an agreement with Malaysia National University (UKM) and are accelerating approval from the Malaysia FDA.

CEO Jung-hwa Kang introduced, "MYJ1633 is an immune cell therapy applicable not only to hematologic cancers and solid tumors but also to autoimmune diseases," adding, "The Ministry of Food and Drug Safety is currently reviewing a phase 1/2a clinical trial that directly administers MYJ1633 to lesions in peritoneally metastasized gastrointestinal cancer."

A representative from NK Biosell said, "We expect that approval from the Malaysia FDA will be possible within 2 to 3 years through cooperation with Immunis Bio," and added, "We anticipate treating more Malaysian patients, as well as patients from neighboring countries, through insurance coverage."

This content was produced with the assistance of AI translation services.